Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy


Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., ...More

MEDICINE, vol.95, no.30, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 95 Issue: 30
  • Publication Date: 2016
  • Doi Number: 10.1097/md.0000000000004280
  • Journal Name: MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Keywords: concomitant chemoradiotherapy, docetaxel-cisplatin, etoposide-cisplatin, locally-advanced NSCLC, lung cancer, VINORELBINE PLUS CISPLATIN, RANDOMIZED PHASE-II, 1ST-LINE TREATMENT, RADIATION-THERAPY, CONCURRENT RADIOTHERAPY, INDUCTION CHEMOTHERAPY, PLATINUM COMBINATIONS, THORACIC RADIATION, STAGE IIIA, TRIAL
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

Presently, there is no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Herein, our aim was to compare the outcome of patients treated with either etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting.